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Background:  Low  back  pain  is  a worldwide  prevalent  musculoskeletal  condition  in the  general  population.
In this  sense,  the  pulsed  electromagnetic  ﬁelds  (PEMF)  therapy  has  shown  signiﬁcant  clinical  beneﬁts  in
several  musculoskeletal  conditions.
Objective:  To assess  the  effectiveness  of  the  PEMF  therapy  in reducing  pain  and  clinical  symptomatology
in  patients  with  low  back  pathological  conditions.
Methods:  It was  performed  a comprehensive  database  search  using  Pubmed,  Scopus,  Cochrane  Library
and  PEDro  databases  to  assess  the  effectiveness  of the  PEMF  therapy  in  reducing  pain  and  clinical  sym-
ptomatology  in patients  with  low  back  pathological  conditions.  The  search  was  performed  from  January
2005  to  August  2015  and  conducted  by  two  independent  investigators,  which  scrutinize  the reference
list  of most  relevant  studies.  The  methodological  quality  was  assessed  by the  PEDro  scale  and  the  level
of  evidence  was  set  according  Oxford  Center  for Evidence-Based  Medicine  scale.
Results:  Six  studies  were  eligible  inclusion  on the  qualitative  analysis  and  ﬁve  into  the  quantitative  analy-
sis, scoring  an  overall  6.8 points  according  the  PEDro  scale.  The  studies  showed  heterogeneity  concerning
the  intervention  protocols.  Nevertheless,  the  effect  sizes’  indicated  a  clear  tendency  to reduction  of  the
pain  intensity  favoring  the PEMF  groups,  reaching  a  minimal  clinically  important  difference.
Conclusion:  PEMF  therapy  seems  to  be  able to relieve  the  pain  intensity  and  improve  functionality  in
individuals  with  low  back pain  conditions.  Further  research  is needed  regarding  PEMF  effects  on  the
different  conditions  of  low  back  pain,  with  standardized  protocols,  larger  samples  and  adjustment  for
low  back  pain  confounders  in  order  to achieve  stronger  conclusions.
© 2016  PBJ-Associac¸a˜o  Porto  Biomedical/Porto  Biomedical  Society.  Published  by  Elsevier  Espan˜a,
S.L.U.  This  is an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/Abbreviations: PEMF, pulsed electromagnetic ﬁeld; NSAIDs, non-steroidal anti-inﬂa
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Table 1
Example of search strategy for Pubmed database.
Search Search term(s) Results
#1 Search pulsed electromagnetic ﬁeld therapy 342
#2  Search back 86,722
#3  Search spine 82,093
#4  Search spinal 120,484
#5  Search lumbar 43,342R. Andrade et al. / Porto 
ntroduction
Low back pain is a very common health problem in general pop-
lation and one of the major reasons for medical treatment seeking.
t is expected that between 60 and 80% of the world population will
xperience low back pain during lifetime,1 with 65% being recur-
ent and longstanding episodes. Low back pain can be caused by
ifferent etiologies, such as muscle or ligament strains, herniated
iscs, arthritis, alteration in the curvature of the spine or osteo-
orosis related fractures but, the majority of the patients do not
ave a clinically identiﬁed problem.2 Despite the variety of treat-
ents available, no modality or therapeutic approach has stand
ut as a deﬁnitive solution.3 Thus, there is still a demand for new
pproaches, less invasive and free of side effects.
The risk/beneﬁt ratio in pharmacotherapy for low back pain
onditions often does not have strength enough to persist with
he drugs usage. Moreover, the risk of pharmacologic addition,
otential side-effects and adverse events, as well as long-term tox-
city may  weaken the potential beneﬁt of the pharmacotherapy
pproach.4,5 In this sense, the pulsed electromagnetic ﬁelds (PEMF)
herapy can play an important role in the pain relief since is a
rug-free, non-thermal, with low risk that works to enhance cel-
ular activity healing and repair.3 Therefore, it could be an option
o the non-steroidal anti-inﬂammatory drugs (NSAIDs) medication,
voiding several potential side-effects from chronic NSAIDs usage.
The PEMF therapy is based in low frequency signal, with a wide
ange of frequencies, which will produce membrane disturbances
nd activation of multiple intracellular pathways.6,7
It has been reported that PEMF therapy yields several beneﬁts
nto the bone uniﬁcation, acute pain relief, wound healing, edema
nd inﬂammation control, as well as, chronic pain associated with
onnective tissue (cartilage, tendon, ligaments and bone) injury
nd joint-associated soft tissue injury, osteoarthritis, ﬁbromyal-
ia, osteoporosis, skin ulcers and further potential applications.8–11
long this line, many reviews have been performed to assess the
EMF effectiveness in several conditions. In this sense, the PEMF
howed moderate7 or no beneﬁts in knee osteoarthritis,12 a bene-
cial tendency on the bone growth stimulation in acute fractures13
nd efﬁcient in relieving pain and enhancing bone formation in
steoporosis.14
Although the use of PEMF therapy in low back pain is growing
nd there is substantial investigation on this topic, a systematiza-
ion of its effects on the low back pain is still lacking. Therefore, this
tudy aims to search for randomized controlled trials that assessed
he effectiveness of the PEMF therapy in reducing pain symptoma-
ology in patients with low back pathological conditions.
ethods
earch strategy
The systematic review was conducted according the Pre-
erred Reporting Items for Systematic Reviews and Meta-Analyses
PRISMA) statement, which aims to improve the standard of repor-
ing of systematic reviews and meta-analyses.15 Additionally, the
rotocol for this review was à priori registered in the Interna-
ional Prospective Register of Systematic Reviews (PROSPERO)
http://www.crd.york.ac.uk/prospero/; ID: CRD42015025308).
It was conducted a comprehensive database search using
ubmed, Scopus, Cochrane Library and PEDro, searching for rel-
vant studies that assessed the efﬁcacy of the PEMF therapy on
educing pain on individuals with low back pain. The search was
erformed according the following key-words: pulsed electro-
agnetic ﬁeld therapy; back; spine; spinal; lumbar; and further
ombined with the Boolean operators (AND; OR). An example of#6  Search (#2 OR #3 OR #4 OR #5) 237,516
#7  Search (#1 AND #6) 32
the search can be seen in Table 1. The reference list of most rele-
vant studies was scanned for additional studies in order to achieve
the greatest number of available studies on the scientiﬁc litera-
ture. All searches were comprised to the period of January 2005 to
August 2015 and were conducted by two  independent investigators
(R.A., H.D.), which confronted both results to check for overlap-
ping; any disagreements were discussed by until consensus was
reached.
Study selection
All titles and abstracts from the selected databases were
screened. After, the potential relevant studies were selected and
retrieved, full texts were read in order to apply the eligibility
according the following inclusion criteria: (1) assessment of pain
outcome; (2) use of pulsed electromagnetic ﬁeld therapy; (3)
prospective design; (4) randomized controlled trials; (5) English
language studies. For exclusion criteria it was  determined: (i) other
reviews or meta-analyses; (ii) clinical commentaries or expert
opinions; (iii) case series; (iv) non-randomized controlled trials;
(v) animal studies; (vi) skeletally immature population.
Data collection and extraction
Two  independent investigators (R.A., H.D.) retrieved all the
information and matched for consensus. The main outcome of
interest was the quantiﬁcation of intensity of pain overtime. Thus,
after the application of the eligibility criteria and the included
studies were determined, the studies were analyzed based on sam-
ple demographics, study’s aim, statement of conﬂict of interest,
study duration and follow-up (period of time and percentage),
PEMF devices used, treatment window, intervention protocol,
parameters assessed (clinical and functional) and most signiﬁcant
results.
In addition, the ﬁgures of pain intensity and the Oswestry Dis-
ability Index were assessed based on their means and standard
deviation values and calculated their mean differences, i.e., dif-
ference between the study’s end-point and baseline values.
Additionally, the Cohen’s effect size, within the 95% conﬁdence
intervals (CI) was calculated. The effect sizes were computed by
subtracting the experimental group mean to the control group
mean and further divided by the pooled standard deviations of
both groups.16,17 Thus, a positive effect reﬂects a greater decrease
on the pain intensity toward the experimental group. The 95% CI
provides information concerning the variability of the observed
effect size, its precision, as well as the accuracy with which the
interval contains the population parameter (i.e., the true value).
The standardized Cohen effect sizes were interpreted according to
the guidelines established by Cohen17 in which values <0.20 are
trivial or not substantial, 0.20 and 0.49 are small but substantial,
0.50 and 0.79 are moderate, and ≥0.80 are large. In case of missing
values (means and/or standard deviations), the authors from the
respective studies were contacted in order to obtain them.
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Records identified through
database searching
(n=91)
Additional records identified
through other sources
(n=3)
Records after duplicates removed
(n=54)
Records screened
(n=54)
Full-text article assessed
for eligibility
(n=12)
Studies included in the
systematic review
(n=6)
Records excluded
(n=38)
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Full-text article excluded, with
reasons (n=6)
No pain intensity evaluation, n=1
German language, n=1
Fibromyalgia, n=1
Lumbar radiculopathy derived lower
limb pain, n=1
Non-radomized controlled trial, n=2
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ethodologic quality assessment
The PEDro scale in order to assess the methodological quality
external validity, internal validity and statistical reporting) and the
evel of evidence was set according the Oxford Center for Evidence-
ased Medicine (CEBM) scale.18 PEDro scale has been reported to
e a valid and reliable tool to measure the methodological quality of
nterventional clinical trials.19,20 These parameters were indepen-
ently assessed by two authors (R.A., H.D.) and all disagreement
ere resolved until consensus was reached.
esults
tudy selection
The database and hand search yielded 91 titles, which were
educed after duplicates removal and title/abstract reading to 12
ull-text articles that were screened for eligibility. After screening,
 studies were excluded21–26 which the reasons for exclusion are
ighlighted in the PRISMA ﬂow chart (Fig. 1). The remaining 6 stud-
es were eligible inclusion on the qualitative analysis and 5 into the
uantitative analysis.
escription of studiesIn Table 2 are presented the characteristics of the 6 included
riginal studies. Overall, the studies included a total of 210 par-
icipants (90 men  and 120 women), with an overall mean age off the eligibility process.
43.3 years old. All the included participants reported complains of
low back pain, however with different etiologies: generalized low
back pain27; acute non-speciﬁc low back pain3; discogenic lumbar
radiculopathy28; failed back surgery syndrome pain26; chronic low
back pain.4,29
The inclusion criteria varied across the studies. Nonetheless,
across the included studies some similarities were found. All of
the studies were performed in adult populations with clinically
evaluated low back pain. A visual analogue scale above 5 points
and a numeric rating scale above 4 points were also considered
in Park, Sun, Lee, Kang, Lee, Hwang and Cha30 and Lee, Kim, Lim,
Lee, Choi, Park, Lee and Lee29 studies, respectively. The presence
of a cardiac pacemaker or other electronic implants were the only
exclusion criteria enclosed in all studies. Other exclusion criteria
were study-speciﬁc related comorbidities.
Generally, the studies enrolled the use of different devices, how-
ever with the same objectives and principles of PEMF therapy
application. Their description can be seen in Table 3. The PEMF
therapy was  often compared with placebo interventions (compris-
ing sham devices) or analgesic medication. Moreover, the studies
showed heterogeneity concerning the PEMF therapy protocols,
where the duration of the application ranged from 5 days to 3
weeks, and the frequency of the application from 4 times a day
to just twice a week. The follow-up period also showed hetero-
geneity, ranging from 3 to 7 weeks,3,4,29,30 or in some cases it was
not reported.27,28 The follow-up percentage was  very satisfactory,
being above the 85%, excepting Oke and Umebese27 study which
did not report the follow-up.
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Table 2
Characteristics and main results of the included studies.
References Demographics Aim Duration/
follow-up
Intervention protocol Treatment window Parameters assessed Results Follow-up
(%)
Krammer et al.3 n = 40
20M/20F
33 y.o.
Explore the additional
beneﬁts of PEME used
as  an adjunct to
physiotherapy in
treatment of acute
non-speciﬁc low back
pain
1  weeks
4 weeks
Experimental group:
physiotherapy and PEME
Control group:
physiotherapy and placebo
7 days of PEME and
physiotherapy 2×/week for
4 weeks
During 7 days ODI; NPRS; Patient
Speciﬁc Functional
Scale; Level of
Function
Both groups showed
improvements on ODI,
Patient Speciﬁc Functional
Scale and NPRS scores over
both follow-up periods
(p < 0.05); however,
without any signiﬁcant
differences between them
(p > 0.05)
100
Park  et al.30 n = 38
11M/27F
32 y.o.
Investigate the efﬁcacy
of PEMF on the lumbar
myalgia
2 weeks
3 weeks
Experimental group: PEMF
Control: sham device
6 times, 3×/week for 2
weeks
10 min day, 3 days a
week, during 2 weeks
VASB; VASP; Korean
version of: ODI;
SF-36; EQ-5D; BDI;
RMDQ
Signiﬁcant decrease of
VASB (p < 0.007), VASP
(p < 0.015) and RMDQ in
PEMF group in comparison
to the control group
100
Oke  et al.27 n = 16
9M/7F
42.8 y.o.
Assess the therapeutic
efﬁcacy of PEMF in
treatment of back pain
5–9 days
N.R.
Experimental group:
analgesics + NSAIDs and
PEMF
Control group: analgesics
Both groups received soft
tissue manipulation with
an analgesic gel
4×/day (2 h)
4 times a day during
2 h (Min 5 days and
Max  9 days of
treatment)
NPRS; Modiﬁed
version of Functional
Activity Scale
Signiﬁcant differences on
experimental group on
pain rating scores
(p > 0.061) and functional
activity score (p > 0.000)
N.R.
Omar  et al.28 n = 40
11M/29F
38.8 y.o.
Evaluate the effect of
PEMF in patients with
discogenic lumbar
radiculopathy
3 weeks
N.R.
Experimental group: PEMF
every day for 3 weeks
Control group: standard
medical treatment and
placebo
20 min day, during 3
weeks
VAS; ODI;
Radiological
evaluation;
Somatosensory
evoked potentials
Signiﬁcant reduction in
pain severity (p < 0.024)
Signiﬁcant improvement in
modiﬁed OSW (p < 0.001)
Improvement of SSEPs
(p < 0.05)
100
Harden et al.4 n = 40
20M/20F
40.3 y.o.
Evaluate the TEMF on
chronic low back pain
2 weeks
6 weeks
Experimental group: TEMF
Control: sham device
40 min session, 10
sessions in 3 weeks
VAS; MPQ-SF; BDI;
STAI; QPDI; Physical
performance tests
Although both groups
improved over time
(p < 0.05), the experimental
group improved
signiﬁcantly over sham
treatment during the
2-week follow-up period
(20.5% reduction in pain,
p = 0.003)
100
Lee  et al.29 n = 36
19M/17F
75 y.o.
Study the effect of
PEMT in patients with
chronic low back pain
3 weeks
7 weeks
Experimental group: active
PEMT
Control group: placebo
3×/week for 3 weeks
The 15-min treatment
3 times a week for 3
weeks
NPRS; Revised ODI PEMT reduced pain and
disability in patients with
chronic low back pain
(p < 0.05)
100
PEME – Pulsed Electromagnetic Energy; PEMF – pulsed electromagnetic ﬁelds; TEMF – Therapeutic Electromagnetic Fields; ODI – Oswestry Disability Index; NPRS – Numeric Pain Rating Scale; M – Male; F – Female; y.o. – years
old;  N.R. – not reported; VAS – visual analogue scale; VASB – visual analogue scale for discomfort for low back pain; VASP – visual analogue scale for pain intensity; SF-36 – Short-Form 36; EQ-5D – EuroQol-5 Dimension (Korean
adapted); BDI – Beck’s Depression Inventory (Korean adapted); RMDQ – Roland-Morris Disability Questionnaire (Korean adapted); NSAIDs – nonsteroidal anti-inﬂammatory drugs; IL-4/IL-6 – interleukins 4 and 6; MPQ-SF –
McGill  Pain Questionnaire – Short Form; BDI – Beck Depression Inventory; STAI – State-Trait Anxiety Inventory; QPDI – Quebec Pain and Disability Index.
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Table 3
PEMF devices used across the included original studies and its reported characteristics.
References Devices Additional reported information
Krammer et al.3 RecoveryRx (BioElectronics Corp) Carrier frequency of this device is 27.12 MHz. Pulse rate of 1000 pulses p/s and
a  100 s burst width. Magnetic ﬂux density or ﬁeld strength of the device is
0.03 mT
Harper et al.26 Provant Therapy System Model 4201 (Regenesis
Biomedical Inc., Scottsdale, AZ, USA)
Carrier frequency of this device is 27.12 MHz. Pulse durations are 42 ± 4 s
repeated every 1000 ± 25 s
Park  et al.30 NUGA MRT-II (NUGA MEDICAL, Wonju, Korea) The maximum strength of PEMF was 820 mT with pulse frequency of 8.56 kHz
Oke  et al.27 EMpulse, Model 301 (EM-Probe Technologies, USA) Non reported
Omar et al.28 NR Field strengths ranged from 5 to 15 Gauss (G) and the frequency ranged from
7  Hz to 4 kHz
Saggini et al.24 NR Electromagnetic ﬁelds of low intensity with inferior frequencies at 100 kHz
Lee  et al.29 CR-3000 system (CR Technology Co., Kyungki-do,
Korea)
Carrier frequency of this device range from 1 to 50 MHz. The magnetic pulse
produced is biphasic and has a pulse width of 270 s. Maximum output
amplitude of 2 T
Table 4
Quantiﬁcation of pain intensity and effect sizes by group.
Reference Control Experimental Effect size (95% CI)
Mean ± SD Mean difference Mean ± SD Mean difference
Krammer et al.3 b 0.77 ± 1.19 −4.14 0.91 ± 0.81 −4.09 −0.14 (−0.76, 0.49)
Park  et al.30 a 6.29 ± 1.33 −0.53 4.53 ± 2.29 −2.1 0.94 (0.25, 1.59)
Oke  et al.27 b 1.63 ± 0.74 −6.62 1.38 ± 1.51 −6.37 0.21 (−0.78, 1.18)
Omar  et al.28 a 5.8 ± 2.7 −1.2 3.6 ± 1.5 −3.5 1.01 (0.33, 1.64)
Lee  et al.29 c 5.4 ± 1.2 −1.1 4.5 ± 1.2 −2.2 0.48 (−0.19, 1.14)
a Visual analogue scale.
b Numeric Pain Rating Scale.
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utcomes of interest
The main outcome of interest was the quantiﬁcation of the
ntensity of low back pain. All studies reported reduction on the
ain intensity, at least, on the experimental group. When assessing
he mean difference on pain intensity from baseline to the end-
oint, it was found a reduction on the pain intensity from 2.1 to
.4 points out of 10 on the visual analogue scale or on the numeri-
al rating pain scale (Table 4); however, when analyzing the effect
izes, two studies showed a small effect size27,29 and two  studies
howed a large effect size.28,30
Regarding the functionality assessment, several scales and
ndexes were used to quantify the participant’s function: Oswestry
isability Index3,28–30; Patient Speciﬁc Functional Scale3; Korean
ersion of Roland-Morris Disability Questionnaire30; Modiﬁed ver-
ion of Functional Activity Scale27; Quebec Pain and Disability
ndex.4 When focusing the Oswestry Disability Index alone, which
as the most commonly reported scale for measuring the func-
ionality, despite its large mean differences from baseline to
nd-points (Table 5), the effect sizes were small (<0.20). The study
f Omar, Awadalla and El-Latif28 was an exception, achieving a large
ffect size (>0.80), however using an adapted Oswestry Disability
ndex.
able 5
swestry Disability Index and effect sizes by group.
Reference Control 
Mean ± SD Mean difference 
Krammer et al.3 6.5 ± 9.08 −28.7 
Park  et al.30 a 16.06 ± 8.79 −13.83 
Omar et al.28 b 48.2 ± 10.09 −25.60 
a Used Korean version of Oswestry Disability Index.
b Used Modiﬁed Oswestry Low Back Pain Disability Questionnaire and presented the reMethodological quality
The mean score of methodological quality of the included stud-
ies was  6.8 ± 1.9 (range 4–9) out of 10 points according PEDro scale
and the level of evidence was 1b in all studies (Table 6).
The most common methodological limitation across the stud-
ies was  the lack of “intention-to-treat” analysis, which was  only
performed by Park, Sun, Lee, Kang, Lee, Hwang and Cha.30 Another
major methodological issue was the concealment of the random-
ization, which also only performed in two  studies.3,30 Lack of
subjects and the assessors blinding was  also a methodological limi-
tation across the studies, especially when concerning the therapist,
once only two  studies blinded the therapists.3,29
Discussion
The main ﬁnding of this systematic review is that PEMF therapy
seems to reduce the pain intensity and enhance better functionality
in individuals with low back pain.
When used alone, the PEMF seem to have great effect in reducing
the pain intensity in low back patients, independently of the low
back pain condition.28–30 However, when added to other standard
Experimental Effect size (95% CI)
Mean ± SD Mean difference
5.7 ± 6.03 −29.9 0.10 (−0.52, 0.72)
14.47 ± 12.39 −13.37 0.15 (−0.49,0.78)
33.4 ± 9.04 −42 1.54 (0.81, 2.21)
sults in percentages.
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Table  6
Methodological quality of the included studies.
References Study design PEDro Oxford CEBM Conﬂict of interest
E 2 3 4 5 6 7 8 9 10 11 Total Level of evidence
Krammer et al.3 Randomized, double-blind,
placebo-controlled trial
+ + + + + + + + − + − 8 1b None
Park  et al.30 Randomized, double-blind,
placebo-controlled trial
+ + + + + − + + + + + 9 1b Corporations
funding
Oke  et al.27 Randomized controlled trial + + − + − − − − − + + 4 1b Missing
Omar et al.28 Randomized controlled trial + + − + − − − + − + + 5 1b None
Harden et al.4 Randomized, single-blind,
placebo-controlled trial
+ + − + + − + + − + + 7 1b Missing
Lee  et al.29 Randomized, double-blind,
placebo-controlled trial
+ + − + + + + + − + + 8 1b None
E: eligibility criteria (this item is not used to calculate the total score); 2: random allocation; 3: concealed allocation; 4: baseline comparability; 5: participant blinding;
6 analys
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d:  therapist blinding; 7: assessor blinding; 8: <15% dropout; 9: intention-to-treat 
tatistical measures.
herapies (such as, standard physiotherapy3 or analgesic therapy27)
eems to do not add additional effect to the standard therapy.
Measuring the intensity of pain related to the different low back
onditions plays a key role in following up the patient’s recov-
ry. However, because of the subjective nature of pain, clinical
mportance is not always easy to determine.31 In an effort to over-
ome this variability, measures of improvement usually adjust
or the individual’s baseline by calculating raw change or percent
hange.32
The PEMF therapy has been pointed out as an effective and rel-
tively safe tool for conservatively treat the low back pain.4,27–30
urthermore, it has a high potential of compliance due to its low
isk of side-effects and high tolerance.29 In fact, when analyzing
he pain intensity alone, the included studies effect sizes indicate
 tendency to a greater reduction on pain intensity for the PEMF
roups. Nevertheless, when compared to standard therapies (such
s, physiotherapy3 or analgesic therapy27) seemed to produce a
ow effect or no effect at all. Considering the minimal clinically
mportant difference (MCID) – minimal change in an outcome score
hat is clinical meaningful for the patients – all studies showed that
he PEMF was able to produce a clinical meaningful pain reduction
ince the mean differences were higher than the minimum 2-point
uggested by Childs, Piva and Fritz.33
Several scoring systems are frequently used in the clinical envi-
onment in order to measure the disability related to the low back
onditions, which should be reliable, valid and sensitive to clinically
elevant changes, taken into account both patients’ and physi-
ians’ perspective and is short and practical to use.34–37 Although,
mpairments such as decreased range of movement or reduced
traight leg raise can be clinically observed by physiotherapists, the
irect observation of activity restriction is not sufﬁcient. Therefore,
he physiotherapists have the need to rely on the patient’s self-
eport assessment to measure the impact of low back pain on daily
ctivities.34
Several studies have been demonstrating the PEMF effective-
ess in reducing the disability related to the low back pain.27–30
egarding the studies included in this systematic review, the dis-
bility assessment was mostly made by the Oswestry Disability
ndex,38 showing improvements after application of PEMF ther-
py, however with small effect sizes. Nevertheless, the MCID’s
ere above the minimum recommended by Ostelo, Deyo, Strat-
ord, Waddell, Croft, Von Korff, Bouter and de Vet39 – between 6–10
oints or 12–20 percent – indicating a meaningful improvement
n the patient’s functionality. On the other hand, Omar, Awadalla
nd El-Latif28 showed a large effect size toward the PEMF group
d = 1.54, 95% CI: 0.81, 2.21) using the Modiﬁed Oswestry Low Back
ain Disability Questionnaire, obtaining a 42% mean reduction after
aily applications of PEMF therapy for 3 weeks. Still, some cautionis; 10: between-group statistical comparisons; 11: point estimate and variability
should be taken when considered this study since they used an
adapted score.
Other usual subjective scores – generic and disease-speciﬁc –
to evaluate the low back functionality have already been explored
during the last decades and are currently available for orthope-
dic clinical and research practice.35 In this sense, beneﬁcial results
were reported in the included studies using different scores: Patient
Speciﬁc Functional Scale3; Korean version of Roland-Morris Dis-
ability Questionnaire30; Modiﬁed version of Functional Activity
Scale27; Quebec Pain and Disability Index.4 Although the studies
showed improvements from the baseline to the study’s end-point,
two studies did not achieved signiﬁcant improvements toward the
PEMF group when compared to the control group.3,4
Due to the comprehensiveness and complexity within the low
back pain umbrella and allied to its associated multiple etiolo-
gies, speciﬁc attention should be directed to the characteristics
of subgroups of responders.4 In this line, the studies included
in our systematic review explored the PEMF therapy effective-
ness in different conditions of low back pain: generalized low
back pain27; acute non-speciﬁc low back pain3; discogenic lum-
bar radiculopathy28; lumbar myalgia30; chronic low back pain.4,29
Due to the high heterogeneity of the different low back pain condi-
tions of the original studies included in this systematic review, and
the small sample sizes (ranging from n = 16 to n = 40), no strong rec-
ommendations can be drawn regarding the non-speciﬁc low back
pain or its several conditions.
Moreover, it was  found high heterogeneity between the proto-
cols of PEMF therapy of the different studies, differing in the devices
used and its parameters (frequency, pulse rate and width, magnetic
ﬂux density, among others), duration and frequency of application
(4 times a day until 3 times a week) and type of application. Hence,
considerable caution should be taken when comparing the results
from the different studies, highlighting the importance in achieve
the most effective dosage and standardized protocol parameters.
In this line, future studies should shift their focus on analyzing
the different mechanisms of action (e.g., myofascial, radiculopathic,
among others) and subgrouping (acute or chronic, speciﬁc or gen-
eralized, mechanical or idiopathic) the individuals with low back
pain in order to evaluate the effects of PEMF therapy in these dif-
ferent groups of low back pain and identify the responsiveness of
each speciﬁc group. Thus, it will be possible to achieve the most
effective PEMF protocol to the most suitable subgroup of patients.
Generally, the studies showed a good methodological quality
according the PEDro scale, with a mean of 6.3 points out of 10 pos-
sible, which is above the recommended by.40 The studies showed a
good methodological quality, i.e., good external and internal valid-
ity, providing sound interpretation of the data. However, precisely
in the internal validity, some limitations were found across the
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tudies that could provide additional bias to the results: lack of
intention-to-treat” analysis; lack of randomization concealment;
ack of blinding of subjects, therapists and assessors. Moreover,
nother important limitation was the statement of conﬂict of inter-
st, where only three studies stated that had no conﬂict of interest
t all. Two other studies did not make any statement about conﬂict
f interest whatsoever and two studies reported funding upon the
tudy’s conduction.
tudy limitations
To the best of our knowledge, no other systematic review has
nvestigated the therapeutic effects of PEMF speciﬁcally on low
ack pain. Moreover, it was used 2 independent reviewers for
creening and critical appraisal and registered our protocol which
ould have reduced the bias within the systematic review. Still,
here are some limitations that are needed to be pointed out. Firstly,
he low number of studies available on the scientiﬁc literature that
nvestigates the effectiveness of PEMF on low back pain is scarce,
nd even fewer if we consider de low back pain subgroups. Another
imitation is the small size of the studies samples, which should be
arger in order to provide power to the conclusion taken from the
esults. Also, the lack of data (means and standard deviation val-
es) was a limitation in some studies, and the wide range of devices
nd low back pain conditions, precluded the systematization of the
uantitative data. The search was restricted to English language
tudies; however, previous work demonstrated that the restriction
o English language studies on systematic reviews does not provide
dditional bias.41–44 Furthermore, the studies did not made an
djustment for confounders (e.g., volume of analgesic medication
onsumption or psychosocial variables), which could lead to fur-
her biased results. These confounders may  mix  with the primary
xposure or outcome and bias the true relationship of interest.45
onclusion
In conclusion, the evidence within this systematic review
emonstrates that the PEMF therapy seems to be able to relieve
he pain and improve functionality in individuals with different low
ack pain conditions. However, when added to a standard therapy,
t seems to do not add any beneﬁcial effect. Nonetheless, due to the
ow risk associated, it can be a potential alternative to the conven-
ional pharmacological therapy. The lack of studies in this theme
arrants further research on PEMF effects on the different condi-
ions of low back pain, with standardized protocols, larger samples
nd adjustment for low back pain confounders in order to achieve
tronger conclusions.
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